Phase II Study of Cyclosporin (Neoral) in Immune Activation and HIV Expression in Early HIV Disease

There is increasing data on the potential for inhibition of immune activation as primary therapy for HIV infection. The rationale of CsA therapy is to decrease T cell activation in patients with early HIV infection. Activation of T cells leads to translation and transcription of provirus, release of viral progeny, and ultimately cell death. T cell activation also leads to increased cell death via apoptosis. CsA is capable of inhibiting both these events and thus may lead to decreased CD4 cell turnover. This study has 2 arms of 15 patients each. Patients in Arm I receive placebo. Patients in Arm II receive CsA. Each arm is further divided into 2 strata. Stratum 1 patients are not allowed to receive antiretroviral therapy. Stratum 2 patients must receive 1 of the following 4 stable nucleoside analogue combinations: 1. Zidovudine (ZDV) plus lamivudine (3TC) 2. ZDV plus didanosine (ddI) 3. Stavudine (d4T) plus 3TC 4. d4T plus ddI.